AAVL: (BN) Avalanche Drops as Gene Therapy Trial Miss High Expectation [CI (Vahe Stepanian, 6/16/2015)mail.com (Daniel Sabba, July 03, 2015)
1 duplicate copy in the archive
EFTA Document EFTA01368453
Title Matchefta-efta01368453
Case Filesd-10-EFTA01368453Dept. of JusticeEFTA Document EFTA01368453
Unknown1p
Case File
sd-10-EFTA01368453Dept. of JusticeEFTA Document EFTA01368453
Other
request. Avalanche Drops as Gene Therapy Trial Miss High Expectations (1) 2015-06.15 21:36:53.569 GMT (Updates with analyst's comment in fourth paragraph.) By Danielle Burger (Bloomberg) -- Avalanche Biotechnologies Inc. shares tumbled after some patients in a safety study of its gene therapy for an age-related chronic eye disease still required injections from another drug. After the company released trial data Monday, shares fell as much as 32 percent to $26.40 in late trading. The stud
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01368453
Pages
1
Persons
0
Integrity
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,800+ persons in the Epstein files. 100% free, donor-supported, and independent. Donors see no ads.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.